BCL2L1 and Miyoshi myopathy: GSEA of the dysregulated genes upon cotreatment with lenalidomide and PDS revealed a significant induction of BMP2 targets, KDM1A/LSD1 targets, B-cell signatures, immune response, and upregulation of genes downregulated in patients with MM overexpressing MYC and BCL2L1 (supplemental Figure 10B).